Running Might Beat Walking For Breast Cancer Survivors Webmd

(adsbygoogle = window.adsbygoogle

New Breast Cancer Surgical Guidelines Can Reduce Unnecessary Procedures and Patient Costs

7, 2014 (HealthDay News) -- Exercise has long been credited with both reducing the risk of stage 3 breast cancer breast cancer and surviving the disease. Now a new study suggests, but doesn't prove, that breast cancer survivors who run have an even greater survival edge than those who walk. "Exercise per se lowers the risk of breast cancer death, but, more importantly, we found a difference between walkers and runners," said study author Paul Williams, a staff scientist at the Lawrence Berkeley National Laboratory in Berkeley, Calif. "We see these huge reductions [in breast cancer deaths] in women who run -- much greater than those who walk," Williams said. "[Even so], we don't see this as negating the benefit of walking ." But running appears to confer more protection than walking in reducing the risk of dying from breast cancer, he said. ..Read more at

'My dog saved my life': Breast cancer patient says her Doberman nuzzled into her chest until she went to the doctor

In 2004, a study by Buckinghamshire Hospitals Trust and the charity Cancer and Bio-detection stages of breast cancer Dogs, found the pets can also detect bladder cancer in urine samples. In January 2011, a study said a specially trained Labrador retriever named Marine had detected colorectal cancer 91 per cent of the time when sniffing patients' breath, and 97 per cent of the time when sniffing stools. Cancer cells are known to produce chemicals called volatile organic compounds which give off distinct odours which dogs are believed to react to. Lung and breast cancer patients are known to exhale biochemical markers which can be traced to tumours that exude substances not found in healthy tissue. As a result, dogs can be trained to point their nose at sample pots they believe are cancerous. ..Read more at

Whether this second procedure is beneficial in reducing the risk of local recurrence, and how much tissue should be removed, has been a topic of ongoing debate in the medical community. To answer this question, Komen provided funding to Dr. Monica Morrow of the SSO to convene leaders in surgical oncology, radiation oncology, medical oncology, pathology and patient advocacy, including representation from Komen's Advocates in Science (AIS) member Peggy Johnson . The panel convened in 2013 to determine the optimal margin width in breast-conserving surgery for stage I and II invasive breast cancer. The findings announced today show that evidence does not support the routine removal of larger amounts of healthy breast tissue beyond the edge of the tumor for any women, including those wth aggressive triple negative breast cancer.SSO and ASTRO are releasing the guidelines to doctors and oncologists today in hopes of influencing clinical practice. ..Read more at